Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Lei, Beilei ^a,b   Dawson, Hana N ^b   Roulhac Wilson, Briana ^a   Wang, Haichen ^a,b   Laskowitz, Daniel T ^a,b   James, Michael L ^a,b  

^a Multidisciplinary Neuroprotection Laboratories   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokine; Intracerebral hemorrhage; Microglia; Murine model; Remicade; Tumor necrosis factor alpha antagonism

Indexed keywords

CASPASE 3; CNTO 5048; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN LEVEL; CELL ACTIVATION; CONTROLLED STUDY; HEMATOMA; HISTOPATHOLOGY; MACROPHAGE MIGRATION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN CLEAVAGE; ROTAROD TEST;

EID: 84883239904     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-103     Document Type: Article

References (48)

1. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001, 57:305-314. 10.1212/WNL.57.2.305, 11468317.
2. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl 2008, 105:147-151. 10.1007/978-3-211-09469-3_30, 19066101.
3. Arima H, Huang Y, Wang JG, Heeley E, Delcourt C, Parsons M, Li Q, Neal B, Chalmers J, Anderson C. Earlier blood pressure-lowering and greater attenuation of hematoma growth in acute intracerebral hemorrhage: INTERACT pilot phase. Stroke 2012, 43:2236-2238. 10.1161/STROKEAHA.112.651422, 22678090.
4. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001, 32:891-897. 10.1161/01.STR.32.4.891, 11283388.
5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008, 358:2127-2137. 10.1056/NEJMoa0707534, 18480205.
6. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397.
7. James ML, Wang H, Venkatraman T, Song P, Lascola CD, Laskowitz DT. Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice. J Neurotrauma 2010, 27:217-228. 10.1089/neu.2009.1022, 19803787.
8. James ML, Blessing R, Phillips-Bute BG, Bennett E, Laskowitz DT. S100B and brain natriuretic peptide predict functional neurological outcome after intracerebral haemorrhage. Biomarkers 2009, 14:388-394. 10.1080/13547500903015784, 2731822, 19505208.
9. Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, Grotta JC, Aronowski J. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol 2007, 61:352-362. 10.1002/ana.21097, 17457822.
10. James ML, Wang H, Cantillana V, Lei B, Kernagis DN, Dawson HN, Klaman LD, Laskowitz DT. TT-301 inhibits microglial activation and improves outcome after central nervous system injury in adult mice. Anesthesiology 2012, 116:1299-1311. 10.1097/ALN.0b013e318253a02a, 22487803.
11. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30. 10.1016/j.clim.2007.08.012, 2291511, 17916445.
12. Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J Neurotrauma 2012, 29:1388-1400. 10.1089/neu.2011.2117, 22233347.
13. James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT. Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke 2009, 40:632-639. 10.1161/STROKEAHA.108.530402, 2699752, 19109539.
14. Laskowitz DT, Lei B, Dawson HN, Wang H, Bellows ST, Christensen DJ, Vitek MP, James ML. The apoE-mimetic peptide, COG1410, improves functional recovery in a murine model of intracerebral hemorrhage. Neurocrit Care 2012, 16:316-326. 10.1007/s12028-011-9641-5, 21989844.
15. Remicade (infliximab) [package insert] 1998, Horsham, PA: Janssen Biotech, Remicade.
16. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994, 11:187-196. 10.1089/neu.1994.11.187, 7932797.
17. Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery 2006, 58:542-550. discussion 542-550.
18. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324. 10.1038/nature09788, 21389984.
19. James ML, Blessing R, Bennett E, Laskowitz DT. Apolipoprotein E modifies neurological outcome by affecting cerebral edema but not hematoma size after intracerebral hemorrhage in humans. J Stroke Cerebrovasc Dis 2009, 18:144-149. 10.1016/j.jstrokecerebrovasdis.2008.09.012, 2699750, 19251191.
20. Sun W, Peacock A, Becker J, Phillips-Bute B, Laskowitz DT, James ML. Correlation of leukocytosis with early neurological deterioration following supratentorial intracerebral hemorrhage. J Clin Neurosci 2012, 19:1096-1100. 10.1016/j.jocn.2011.11.020, 3706635, 22704946.
21. Wagner KR, Xi G, Hua Y, Kleinholz M, de Courten-Myers GM, Myers RE, Broderick JP, Brott TG. Lobar intracerebral hemorrhage model in pigs: rapid edema development in perihematomal white matter. Stroke 1996, 27:490-497. 10.1161/01.STR.27.3.490, 8610319.
22. Yang GY, Betz AL, Chenevert TL, Brunberg JA, Hoff JT. Experimental intracerebral hemorrhage: relationship between brain edema, blood flow, and blood-brain barrier permeability in rats. J Neurosurg 1994, 81:93-102. 10.3171/jns.1994.81.1.0093, 8207532.
23. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JN, Hussein HM, Suri MF, Tariq N. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010, 67:570-576. 10.1001/archneurol.2010.61, 20457956.
24. Perez la de Ossa N, Sobrino T, Silva Y, Blanco M, Millan M, Gomis M, Agulla J, Araya P, Reverte S, Serena J, Davalos A. Iron-related brain damage in patients with intracerebral hemorrhage. Stroke 2010, 41:810-813. 10.1161/STROKEAHA.109.570168, 20185788.
25. NINDS ICH Workshop Participants Priorities for clinical research in intracerebral hemorrhage: report from a National Institute of Neurological Disorders and Stroke workshop. Stroke 2005, 36:e23-41. NINDS ICH Workshop Participants.
26. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, Fiebich BL, Rosenberg GA. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 2007, 323:488-498. 10.1124/jpet.107.127035, 2270866, 17704356.
27. Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett 2007, 425:177-182. 10.1016/j.neulet.2007.08.022, 17825990.
28. Lloyd E, Somera-Molina K, Van Eldik LJ, Watterson DM, Wainwright MS. Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation 2008, 5:28. 10.1186/1742-2094-5-28, 2483713, 18590543.
29. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007, 207:227-237. 10.1016/j.expneurol.2007.06.025, 17698063.
30. Lee ST, Chu K, Sinn DI, Jung KH, Kim EH, Kim SJ, Kim JM, Ko SY, Kim M, Roh JK. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem 2006, 96:1728-1739. 10.1111/j.1471-4159.2006.03697.x, 16539688.
31. Wu J, Yang S, Xi G, Fu G, Keep RF, Hua Y. Minocycline reduces intracerebral hemorrhage-induced brain injury. Neurol Res 2009, 31:183-188. 10.1179/174313209X385680, 2659336, 19061541.
32. Wu J, Yang S, Xi G, Song S, Fu G, Keep RF, Hua Y. Microglial activation and brain injury after intracerebral hemorrhage. Acta Neurochir Suppl 2008, 105:59-65. 10.1007/978-3-211-09469-3_13, 19066084.
33. Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007, 24(Suppl 1):7-15.
34. Castillo J, Davalos A, Alvarez-Sabin J, Pumar JM, Leira R, Silva Y, Montaner J, Kase CS. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology 2002, 58:624-629. 10.1212/WNL.58.4.624, 11865143.
35. Rodriguez-Yanez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 2008, 21:353-357. 10.1097/WCO.0b013e3282ffafbf, 18451722.
36. Mayne M, Ni W, Yan HJ, Xue M, Johnston JB, Del Bigio MR, Peeling J, Power C. Antisense oligodeoxynucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke 2001, 32:240-248. 10.1161/01.STR.32.1.240, 11136943.
37. Aslam M, Ahmad N, Srivastava R, Hemmer B. TNF-alpha induced NFkappaB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 2012, 57:269-275. 10.1016/j.cyto.2011.10.016, 22138107.
38. Niemann JT, Youngquist S, Rosborough JP, Shah AP, Phan QT, Filler SG. Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model. Crit Care Med 2010, 38:1162-7. 10.1097/CCM.0b013e3181d44324, 2845729, 20154606.
39. Watters O, Pickering M, O'Connor JJ. Preconditioning effects of tumor necrosis factor-alpha and glutamate on calcium dynamics in rat organotypic hippocampal cultures. J Neuroimmunol 2011, 234:27-39. 10.1016/j.jneuroim.2011.01.008, 21402417.
40. Onda A, Murata Y, Rydevik B, Larsson K, Kikuchi S, Olmarker K. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine 2004, 29:1857-1861. 10.1097/01.brs.0000137054.08788.b2, 15534405.
41. Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CP, Liu RQ. Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 2004, 65:890-896. 10.1124/mol.65.4.890, 15044618.
42. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997, 778:265-271. 10.1016/S0006-8993(97)00981-5, 9459543.
43. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997, 72:169-177. 10.1016/S0165-5728(96)00181-6, 9042110.
44. Campbell SJ, Jiang Y, Davis AE, Farrands R, Holbrook J, Leppert D, Anthony DC. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response. J Neurochem 2007, 103:2245-2255. 10.1111/j.1471-4159.2007.04928.x, 17883399.
45. Sharma HS. A combination of tumor necrosis factor-alpha and neuronal nitric oxide synthase antibodies applied topically over the traumatized spinal cord enhances neuroprotection and functional recovery in the rat. Ann N Y Acad Sci 2010, 1199:175-185. 10.1111/j.1749-6632.2009.05327.x, 20633123.
46. Hernandez-Romero MC, Delgado-Cortes MJ, Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Arguelles S, Bandez MJ, Villaran RF, Maurino R, Santiago M, et al. Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. Neurotoxicology 2012, 33:347-360. 10.1016/j.neuro.2012.01.018, 22330755.
47. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011, 42:2645-2650. 10.1161/STROKEAHA.111.618850, 21852620.
48. Transparency in Reporting Guidelines http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf.